Lantus and Vitreous detachment - a phase IV clinical study of FDA data

Summary:

Vitreous detachment is reported as a side effect among people who take Lantus (insulin glargine recombinant), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Humalog, and have Vasculitis.

The phase IV clinical study analyzes which people have Vitreous detachment when taking Lantus. It is created by eHealthMe based on reports of 190,478 people who have side effects when taking Lantus from the FDA, and is updated regularly.

What is Lantus?

Lantus has active ingredients of insulin glargine recombinant. It is often used in diabetes. eHealthMe is studying from 191,782 Lantus users. Check the latest studies of Lantus.

What is Vitreous detachment?

Vitreous detachment (a condition of the eye in which the vitreous humour separates from the retina) is found to be associated with 411 drugs and 457 conditions by eHealthMe. Check the latest studies of Vitreous detachment.

On Aug, 05, 2026

190,478 people reported to have side effects when taking Lantus.
Among them, 48 people (0.03%) have Vitreous detachment.

Among these 48 people:

How long have people been on Lantus when they have Vitreous detachment? *

What is the gender of people who have Vitreous detachment when taking Lantus? *

female: 70.73 %
male: 29.27 %

What is the age of people who have Vitreous detachment when taking Lantus? *

What are other drugs people take besides Lantus? *

What are other side effects people have besides Vitreous detachment? *

Blood Glucose Increased: 18 people, 37.50%
Vision Blurred: 17 people, 35.42%
Dyspnea (difficult or laboured breathing): 16 people, 33.33%
Dehydration (dryness resulting from the removal of water): 16 people, 33.33%
Head Injury: 14 people, 29.17%
Renal Impairment (severely reduced kidney function): 12 people, 25.00%
Hypoglycemia (low blood sugar): 12 people, 25.00%
Weight Increased: 12 people, 25.00%
Oedema (fluid collection in tissue): 11 people, 22.92%
Monocyte Count Increased: 11 people, 22.92%

What are the existing conditions these people have? *

Vasculitis (inflammation of a blood vessel or blood vessels): 11 people, 22.92%
Arrhythmias (irregular heartbeat): 7 people, 14.58%
Gout (uric acid crystals building up in the body): 5 people, 10.42%
Diabetic Retinopathy (damage to the retina caused by complications of diabetes): 4 people, 8.33%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 6.25%
High Blood Cholesterol: 3 people, 6.25%
High Blood Pressure: 3 people, 6.25%
Kidney Stones: 2 people, 4.17%
Cystitis Interstitial (unknown cause characterized by bladder pain): 2 people, 4.17%
Retinal Oedema (swelling of retina): 2 people, 4.17%

* Approximation only. Some reports may have incomplete information.

Do you take Lantus and have Vitreous detachment?

- Check whether Vitreous detachment is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lantus:

Lantus (191,782 reports)

Browse all side effects of Lantus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Vitreous detachment:

Vitreous detachment (411 drugs)

Browse all the conditions that are associated with Vitreous detachment:

Vitreous detachment (457 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on insulin glargine recombinant (the active ingredients of Lantus) and Lantus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.